Irene Graf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irene Graf has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Susanne Herndlhofer
Division of Hematology and Hemostaseology, Department of Internal Medicine I Medical University of Vienna Vienna Austria
3 shared publications- Wolfgang R. Sperr
Medical University of Vienna
3 shared publications Alexander Hauswirth
Division of Hematology and Hemostaseology, Department of Internal Medicine I Medical University of Vienna Vienna Austria
2 shared publications- Georg Greiner
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
2 shared publications - Karoline Veronika Gleixner
Department of Internal Medicine I, Division of Hematology and Hemostaseology Medical University of Vienna, Vienna, Austria
2 shared publications Michael Kundi
Institute of Environmental Health Medical University of Vienna Vienna Austria
2 shared publications
Latest Publications
- Open Access
- 1 January 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (2) , 290-299
N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
Patient‐related factors are of prognostic importance in acute myeloid leukemia (AML). Likewise, cardiac disorders may limit the tolerance of intensive therapy. Little is known about the prognostic value of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). We analyzed NT‐proBNP levels at diagnosis in 312 AML patients (median age: 61 years; range 17–89 years) treated with 3 + 7‐based induction‐chemotherapy and consolidation with up to four cycles of intermediate or high‐dose ARA‐C. NT‐proBNP levels were elevated in 199 patients (63.8%), normal (0–125 pg/ml) in 113 (36.2%), and highly elevated (>2000 pg/ml) in 20 patients (6.4%). Median NT‐proBNP levels differed significantly among patients with complete remission (153.3 pg/ml), no remission (225.9 pg/ml), or early death (735.5 pg/ml) (p = .002). In multivariate analysis, NT‐proBNP, age, and the 2009 European LeukemiaNet (ELN‐2009) classification were independent predictors of outcome after induction chemotherapy. Overall survival (OS) differed significantly between patients with normal, moderately elevated, and highly elevated NT‐proBNP (p < .001). These differences were observed in all patients and in patients p < .01). Together, NT‐proBNP is an independent prognostic factor indicating the risk of induction failure, early death, and reduced OS in patients with AML.
- 1 January 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (2) , 290-299
Open AccessN‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
Patient‐related factors are of prognostic importance in acute myeloid leukemia (AML). Likewise, cardiac disorders may limit the tolerance of intensive therapy. Little is known about the prognostic value of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). We analyzed NT‐proBNP levels at diagnosis in 312 AML patients (median age: 61 years; range 17–89 years) treated with 3 + 7‐based induction‐chemotherapy and consolidation with up to four cycles of intermediate or high‐dose ARA‐C. NT‐proBNP levels were elevated in 199 patients (63.8%), normal (0–125 pg/ml) in 113 (36.2%), and highly elevated (>2000 pg/ml) in 20 patients (6.4%). Median NT‐proBNP levels differed significantly among patients with complete remission (153.3 pg/ml), no remission (225.9 pg/ml), or early death (735.5 pg/ml) (p = .002). In multivariate analysis, NT‐proBNP, age, and the 2009 European LeukemiaNet (ELN‐2009) classification were independent predictors of outcome after induction chemotherapy. Overall survival (OS) differed significantly between patients with normal, moderately elevated, and highly elevated NT‐proBNP (p < .001). These differences were observed in all patients and in patients p < .01). Together, NT‐proBNP is an independent prognostic factor indicating the risk of induction failure, early death, and reduced OS in patients with AML.
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 11634-11635
Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies
Introduction: Without transplantation, survival of patients (pts) with relapsed acute myeloid leukemia (AML) after chemotherapy is poor. However, some pts may b
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 11634-11635
Open AccessDelineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies
Introduction: Without transplantation, survival of patients (pts) with relapsed acute myeloid leukemia (AML) after chemotherapy is poor. However, some pts may b
- Open Access
- 17 October 2022
- Published by Wiley in European Journal of Haematology
- Vol. 110 (1) , 67-76
Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
Background The SARS-COV-2 (Covid-19) pandemic has impacted the management of patients with hematologic disorders. In some entities, an increased risk for Covid-19 infections was reported, whereas others including chronic myeloid leukemia (CML) had a lower mortality. We have analyzed the prevalence of Covid-19 infections in patients with mastocytosis during the Covid-19 pandemic in comparison to data from CML patients and the general Austrian population. Materials and Methods The prevalence of infections and PCR-proven Covid-19 infections was analyzed in 92 patients with mastocytosis. As controls, we used 113 patients with CML and the expected prevalence of Covid-19 in the general Austrian population. Results In 25% of the patients with mastocytosis (23/92) signs and symptoms of infection, including fever (n = 11), dry cough (n = 10), sore throat (n = 12), pneumonia (n = 1), and dyspnea (n = 3) were recorded. Two (8.7%) of these symptomatic patients had a PCR-proven Covid-19 infection. Thus, the prevalence of Covid-19 infections in mastocytosis was 2.2%. The number of comorbidities, subtype of mastocytosis, regular exercise, smoking habits, age, or duration of disease at the time of interview did not differ significantly between patients with and without Covid-19 infections. In the CML cohort, 23.9% (27/113) of patients reported signs and symptoms of infection (fever, n = 8; dry cough, n = 17; sore throat, n = 11; dyspnea, n = 5). Six (22.2%) of the symptomatic patients had a PCR-proven Covid-19 infection. The prevalence of Covid-19 in all CML patients was 5.3%. The observed number of Covid-19 infections neither in mastocytosis nor in CML patients differed significantly from the expected number of Covid-19 infections in the Austrian population. Conclusions Our data show no significant difference in the prevalence of Covid-19 infections among patients with mastocytosis, CML, and the general Austrian population and thus, in mastocytosis, the risk of a Covid-19 infection was not increased compared to the general population.
- 17 October 2022
- Published by Wiley in European Journal of Haematology
- Vol. 110 (1) , 67-76
Open AccessIncidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
Background The SARS-COV-2 (Covid-19) pandemic has impacted the management of patients with hematologic disorders. In some entities, an increased risk for Covid-19 infections was reported, whereas others including chronic myeloid leukemia (CML) had a lower mortality. We have analyzed the prevalence of Covid-19 infections in patients with mastocytosis during the Covid-19 pandemic in comparison to data from CML patients and the general Austrian population. Materials and Methods The prevalence of infections and PCR-proven Covid-19 infections was analyzed in 92 patients with mastocytosis. As controls, we used 113 patients with CML and the expected prevalence of Covid-19 in the general Austrian population. Results In 25% of the patients with mastocytosis (23/92) signs and symptoms of infection, including fever (n = 11), dry cough (n = 10), sore throat (n = 12), pneumonia (n = 1), and dyspnea (n = 3) were recorded. Two (8.7%) of these symptomatic patients had a PCR-proven Covid-19 infection. Thus, the prevalence of Covid-19 infections in mastocytosis was 2.2%. The number of comorbidities, subtype of mastocytosis, regular exercise, smoking habits, age, or duration of disease at the time of interview did not differ significantly between patients with and without Covid-19 infections. In the CML cohort, 23.9% (27/113) of patients reported signs and symptoms of infection (fever, n = 8; dry cough, n = 17; sore throat, n = 11; dyspnea, n = 5). Six (22.2%) of the symptomatic patients had a PCR-proven Covid-19 infection. The prevalence of Covid-19 in all CML patients was 5.3%. The observed number of Covid-19 infections neither in mastocytosis nor in CML patients differed significantly from the expected number of Covid-19 infections in the Austrian population. Conclusions Our data show no significant difference in the prevalence of Covid-19 infections among patients with mastocytosis, CML, and the general Austrian population and thus, in mastocytosis, the risk of a Covid-19 infection was not increased compared to the general population.